|
Market Closed -
Nasdaq
16:00:00 2025-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 100.99 USD | +0.01% |
|
-.--% | - |
| Market Cap | 3.32B 2.89B 2.74B 2.49B 4.65B 318B 4.67B 32.61B 12.61B 162B 12.48B 12.2B 517B | P/E 2023 |
-317x | P/E 2024 | 69.3x |
|---|---|---|---|---|---|
| Enterprise Value | 3.48B 3.03B 2.87B 2.6B 4.87B 333B 4.89B 34.14B 13.2B 169B 13.06B 12.77B 542B | EV / Sales 2023 |
1.55x | EV / Sales 2024 | 1.33x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
| 25-09-30 | A CEO's Playbook For Navigating Crisis And Building Trust (Video) | AQ |
| 25-07-29 | Amedisys: Q2 Earnings Snapshot | AQ |
| 25-07-29 | Amedisys : Second Quarter 2025 Earnings Release Supplemental Slides | PU |
| 25-07-29 | Amedisys Reports Second Quarter 2025 Financial Results | AQ |
| 25-04-23 | Amedisys: Q1 Earnings Snapshot | AQ |
| 1 day | +0.01% |
| 3 years | 82.15 |  | 101.02 |
| 5 years | 69.36 | | 188.88 |
| 10 years | 34.58 | | 325.12 |
| Manager | Title | Age | Since |
|---|---|---|---|
Scott Ginn
DFI | Director of Finance/CFO | 57 | 2017-10-05 |
Keith Blanchard
CTO | Chief Tech/Sci/R&D Officer | - | - |
Denise Bohnert
CMP | Compliance Officer | 48 | 2016-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/14/25 | Issuer sale | Director | 9,818 | 0.0300% | ||
| 8/14/25 | Issuer sale | Director | 9,818 | 0.0300% | ||
| 8/14/25 | Issuer sale | Chief Executive Officer | 520,347 | 1.5886% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 2.24B 1.95B 1.84B 1.67B 3.13B 214B 3.14B 21.96B 8.49B 109B 8.4B 8.21B 348B | 2.35B 2.05B 1.94B 1.76B 3.29B 225B 3.3B 23.06B 8.92B 114B 8.82B 8.63B 366B |
| Net income | -9.75M -8.49M -8.03M -7.3M -13.64M -933M -13.71M -95.7M -37.01M -474M -36.62M -35.8M -1.52B | 43.23M 37.65M 35.64M 32.38M 60.49M 4.14B 60.79M 424M 164M 2.1B 162M 159M 6.74B |
| Net Debt | 361M 314M 297M 270M 505M 34.55B 507M 3.54B 1.37B 17.56B 1.36B 1.33B 56.21B | 156M 136M 129M 117M 218M 14.95B 219M 1.53B 592M 7.6B 586M 573M 24.32B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- AMED Stock
Select your edition
All financial news and data tailored to specific country editions
